Pregled bibliografske jedinice broj: 923516
Azithromycin in prophylaxis of Mediterranean Spotted Fever
Azithromycin in prophylaxis of Mediterranean Spotted Fever // Vth International Symposium: Rickettsiae and Rickettsial Diseases
Bratislava, Slovačka, 1996. str. 266-271 (predavanje, međunarodna recenzija, cjeloviti rad (in extenso), znanstveni)
CROSBI ID: 923516 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Azithromycin in prophylaxis of Mediterranean Spotted Fever
Autori
Dželalija, Boris ; Morović, Miro ; Avšič-Županc, Tatjana ; Zrnić, Tatjana
Vrsta, podvrsta i kategorija rada
Radovi u zbornicima skupova, cjeloviti rad (in extenso), znanstveni
Izvornik
Vth International Symposium: Rickettsiae and Rickettsial Diseases
/ - , 1996, 266-271
Skup
Vth International Symposium: Rickettsiae and Rickettsial Diseases
Mjesto i datum
Bratislava, Slovačka, 01.09.1996. - 06.09.1996
Vrsta sudjelovanja
Predavanje
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Mediterranean Spotted Fever ; Rickettsia conorii ; tick ; Azithromycin ; prophylaxis
Sažetak
An, open controlled study was conducted in North Dalmatia (Croatia), to assess the efficacy of azithromycin (Sumamed, Pliva)in prophylaxis of Mediterranean spotted fever, (MSF) in 124 persons with history of recent tick bite during 1994 and 1995. Indirect immunofluorescence assay (IFA), was performed to detect Rickettsia conorii antibodies in 124 individuals who met inclusion criteria. Patients were divided in two groups: in group A 38 patients received 500 mg of azithromycin and in group B 86 patients didn’t receive any antibiotic prophylaxis. None of the patients in group A developed any clinical sings of MSF were positive titers of IFA antibodies at the ends the opservation period were detected in 12/38 (31.2%) patients. The usual clinical signs of MSF were observed in 22/86 (25.6%), and positive titers of R. conorii antibodies in 52/85 (60.5%) patients in group B. Because of high prevalence of R. conorii infected ticks in North Dalmatian region use of azithromycin in prophylaxis of MSF make sense and further investigation is needed to consolidate our principal results
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)